{平台标识} Investors can follow market trends through daily updates on earnings results, stock volatility, and sector performance. BioOrbit, a British biotechnology startup, has sent its drug-crystallisation technology to the International Space Station (ISS) aboard a SpaceX flight, aiming to produce ultra-pure protein crystals for self-injected cancer treatments. The company’s compact Box-E unit, about the size of a microwave, could potentially revolutionise the stability and delivery of biologic drugs, saving millions in manufacturing costs.
UK Startup BioOrbit Launches Drug Manufacturing to Space with SpaceX, Targeting Self-Injected Cancer Therapies - {财报副标题}
News Analysis
© 2026 Market Analysis. All data is for informational purposes only.